Success Metrics

Clinical Success Rate

62.5%

Based on 5 completed trials

Completion Rate

63%(5/8)

Active Trials

0(0%)

Results Posted

100%(5 trials)

Terminated

3(38%)

Phase Distribution

Ph phase_3

13%

Ph phase_2

63%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

2(25.0%)

Phase 2Efficacy & side effects

5(62.5%)

Phase 3Large-scale testing

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(3)

Detailed Status

Completed5

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

62.5%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (25.0%)

Phase 25 (62.5%)

Phase 31 (12.5%)

Trials by Status

completed563%

terminated338%

Recent Activity

0 active trials

Showing 5 of 8

terminatedphase_2

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension

NCT04004000

terminatedphase_3

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

NCT05397470

terminatedphase_2

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

NCT04264442

completedphase_2

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01218126

completedphase_1

PK Study of IV Formulation of GW856553

NCT01039961

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT04004000Phase 2

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension

Terminated

NCT05397470Phase 3

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Terminated

NCT04264442Phase 2

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Terminated

NCT01218126Phase 2

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Completed

NCT01039961Phase 1

PK Study of IV Formulation of GW856553

Completed

NCT02000440Phase 2

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Completed

NCT01756495Phase 1

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

Completed

NCT01541852Phase 2

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.